News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Americans



7/9/2008 12:37:08 PM

GAITHERSBURG, MD--(Marketwire - July 9, 2008) - Sigma-Tau Pharmaceuticals, Inc. is pleased to announce the acquisition of Chenofalk® (chenodeoxycholic acid) from the Germany-based, Dr. Falk Pharma GmbH. Chenofalk® is approved in Germany for the dissolution of gallstones, and Sigma-Tau's German affiliate, Sigma-Tau Arzneimittel GmbH, will immediately assume distribution of this important medicine, ensuring there is no interruption in availability to patients.

Read at Market Wired


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES